# US 2026/0096959 A1 · Method for Producing Silver Nanoparticles in an Active Carious Lesion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0096959 A1
- Document ID: US20260096959A1
- Status: Published application
- Kind: A1
- Application number: 19/345,469
- Filed: 2025-09-30
- Published: 2026-04-09
- Earliest claimed: 2024-10-03
- Assignees: R.M Creighton Dental Pty Ltd
- Applicants: R.M Creighton Dental Pty Ltd
- Inventors: Graham G. Craig
- Web page: https://patentgrep.com/patent/US20260096959A1

## CPC

- A61K 8/19: containing inorganic ingredients
- A61K 8/0241: {Containing particulates characterized by their shape and/or structure (see also A61K8/04, A61K8/11, and A61K8/14, further aspects are classified in A61K2800/40 and subcodes)}
- A61K 8/21: Fluorides; Derivatives thereof
- A61K 8/345: {containing more than one hydroxy group}
- A61Q 11/00: Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- A61K 2800/413: Nanosized, i.e. having sizes below 100 nm
- A61K 2800/92: Oral administration
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

A method of treating a carious lesion in a tooth which includes a step of applying a first dental solution to the carious lesion of the tooth, applying a second dental solution to the treated carious lesion within less than 10 minutes of the step of applying the first dental solution. The treated carious lesion consolidates forming a crust having a matte black surface and comprising nanoparticles after about 3-5 weeks. The first dental solution comprises an organic or inorganic silver salt and the second dental solution comprises an organic or inorganic reducing agent.

## Claims

### Claim 1

A method of treating an active carious lesion in a tooth comprising steps of:
applying a first dental solution to the carious lesion of the tooth,
applying a second dental solution to the treated carious lesion within less than 10 minutes of the step of applying the first dental solution,
wherein the treated carious lesion consolidates forming a crust having a matte black surface and comprising silver nanoparticles within about 3-5 weeks after application of the first and second dental solutions, and
wherein the first dental solution comprises an organic or inorganic silver salt and the second dental solution comprises an organic or inorganic reducing agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 99% of the nanoparticles have an absolute diameter of 100 nanometers or less, wherein the absolute diameter is measured using high resolution transmission electron microscopy of serial sections prepared from the crust.

### Claim 3

The method of any one of the previous claims, wherein the nanoparticles comprise silver.

### Claim 4

The method of any one of the previous claims, wherein
the first dental solution comprises silver fluoride; silver fluoride stabilized with nitric acid; silver nitrate; silver diamine fluoride (silver diammine fluoride); silver diammine fluoride stabilized with ammonia; silver diammine nitrate stabilized with ammonia; or a mixture of silver nitrate, boron fluoride, hydrofluoric acid and ammonia hydroxide, and
the second dental solution comprises stannous fluoride.

### Claim 5

The method of any one of the previous claims, wherein the second dental solution comprises stannous fluoride and the first dental solution comprises a mixture of silver fluoride and nitric acid.

### Claim 6

The method of any one of the previous claims, wherein the first dental solution comprises silver fluoride stabilized with nitric acid and the nitric acid is added in sufficient quantity to substantially stabilize the silver fluoride in solution such that the silver ion levels do not decrease by more than 5% over a period of at least 24 months at approximately 25° C.

### Claim 7

The method of any one of the previous claims, wherein the first dental solution comprises silver fluoride and is formed in a process comprising dissolving silver fluoride powder in deionized water and removing particulates with a filter to form a filtrate comprising aqueous silver fluoride.

### Claim 8

The method of any one of the previous claims, wherein the deionized water has a resistivity of 18.2 MΩ·cm, TOC<10 ppb and bacterial count <10 CFU/ml.

### Claim 9

The method of any one of the previous claims, wherein the first dental solution comprises silver fluoride and further comprises combining the silver fluoride with nitric acid until a pH of the first dental solution is 4.0-6.0, or 5.5-6.0.

### Claim 10

The method of any one of the previous claims, wherein the first dental solution comprises silver diamine fluoride wherein the silver diammine fluoride comprises between 1%-50% w/v silver fluoride.

### Claim 11

The method of any one of the previous claims, wherein the first dental solution comprises silver diammine fluoride and is made by dissolving silver fluoride powder in water with the pH adjusted with ammonia between 1%-28% w/v.

### Claim 12

The method of any one of the previous claims, wherein the reducing agent is stannous fluoride, which is formed in a process comprising,
step (a) heating anhydrous glycerol to >140° C. to prepare heated glycerol,
step (b) adding D-sorbitol powder to the heated glycerol of step (a) while stirring to form a first mixture,
step (c) adding powdered stannous fluoride to the first mixture while stirring, and
step (d) continue stirring for 20 minutes to 40 minutes until stannous fluoride is dissolved.

### Claim 13 (depends on 12)

The method of claim 12, further comprising pulverizing the stannous fluoride before step (c).

### Claim 14 (depends on 12, 13)

The method of any one of claims 12-13, wherein the temperature of step (a) is at least 170° C., or about 180° C.

### Claim 15 (depends on 12, 13, 14)

The method of any one of claims 12-14, wherein an amount of D-sorbitol is 1-10 w/v %, or about 5 w/v % in the reducing agent.

### Claim 16

The method of any one of the previous claims, wherein the second dental solution comprises an amount of stannous fluoride of from 1-50 w/v %, or from 5-25 w/v %, or from about 10 w/v % in the reducing agent.

### Claim 17

The method of any one of the previous claims, wherein the first dental solution comprises between 1%-50% w/v silver fluoride, or 20%-49% w/v silver fluoride, or 30%-45% w/v silver fluoride.

### Claim 18

The method of any one of the previous claims, wherein the inorganic reducing agent is a metallic salt.

### Claim 19

The method of any one of the previous claims, wherein the inorganic reducing agent is between 1%-50% w/v stannous fluoride.

### Claim 20

The method of any one of the previous claims, wherein the metallic salt is at least one of ferrous fluoride or potassium iodide.

### Claim 21

The method of any one of the previous claims, wherein the reducing agent comprises 1%-50% w/v of the metallic salt.

### Claim 22

The method of any one of the previous claims, wherein the reducing agent is made without added water, and optionally has added glycerol.

### Claim 23

The method of any one of the previous claims, wherein the reducing agent comprises up to 100% w/v glycerol in the reducing agent, and between 1% to 20% w/v sorbitol in the reducing agent.

### Claim 24

The method of any one of the previous claims, wherein the reducing agent is mechanically mixed.

### Claim 25

The method of any one of the previous claims, wherein the organic reducing agent comprises at least one of tannic acid, a polyphenol, eugenol, a phenylpropanoid, an oligosaccharide, a polysaccharide, a monosaccharide and a disaccharide, a polyethylene glycol, and lactic acid bacteria (Lactobacillus genus).

### Claim 26 (depends on 25)

The method of claim 25, wherein the monosaccharide comprises at least one of aldoses and ketoses classes of organic chemical compounds, and the disaccharide comprises at least one of lactose, maltose, and calcium sucrose phosphate.

### Claim 27 (depends on 25, 26)

The method of any one of claims 25-26, wherein the monosaccharide comprises dietary monosaccharides with at least one of galactose, glucose, or fructose.

### Claim 28 (depends on 25, 26, 27)

The method of any one of claims 25-27, wherein the oligosaccharide comprises at least one of starch or starch derivative, and wherein at least one of starch and starch-derivative comprise at least one of glucose syrup, maltodextrin, or dextrin.

### Claim 29 (depends on 25, 26, 27, 28)

The method of any one of claims 25-28, wherein the polysaccharide(non-sugars) comprises at least one of cellulose, starch, glycogen, or chitin.

### Claim 30

The method of any one of the previous claims, wherein the organic reducing agent is an artificial sweetener/sugar substitute which can be made in the laboratory.

### Claim 31 (depends on 30)

The method of claim 30, wherein the sugar substitute/artificial sweetener is based on at least one of dextrose, maltodextrin, or sucralose.

### Claim 32

The method of any one of the previous claims, wherein the reducing agent is a flowing solution which can be applied with a microbrush in volumes as low as 0.01 ml and contains at least one suitable flavouring agent.

### Claim 33

The method of any one of the previous claims, wherein the carious lesion is in a tooth of a mammal, or wherein the carious lesion is in a tooth of a human.
